Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

Launched by ASAN MEDICAL CENTER · Nov 24, 2015

Keywords

ClinConnect Summary

This clinical trial is investigating how advanced MRI (magnetic resonance imaging) techniques can help doctors see how well standard treatments are working in patients with newly diagnosed glioblastoma, a type of brain cancer. The aim is to find out if these imaging methods can predict how patients will respond to treatment in the long run. The trial is currently recruiting participants aged 65 to 74 who have been diagnosed with glioblastoma and have measurable tumors visible on MRI scans. To join, patients should be planning to start standard therapy, which includes radiation treatment and a specific chemotherapy drug.

Participants in this trial will have advanced MR imaging done to track their treatment response. It's important that they understand the study and agree to participate by signing consent forms. However, certain patients, such as those who have had surgery that removed all the visible tumor, or those with certain medical devices, may not be eligible. This study could provide valuable insights into how best to treat glioblastoma, potentially improving outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have radiologically and histologically confirmed diagnosis of newly diagnosed glioblastoma
• • Patients must have measurable disease, defined as evident tumors with gadolinium enhancement on MRI that is measurable in at least one diameter
• • Life expectancy of greater than 3 months
• • Patients scheduled for standard therapy (6 weeks radiation treatment (RT) \~ 60 Gy, plus temozolomide 75 mg/m\^2 during 6 week RT, and followed routine monthly temozolomide therapy)
• • Ability to understand and the willingness to sign a written informed consent document; all patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines
• Exclusion Criteria:
• • Patients who underwent complete resection
• • Patients with no evidence of measurable disease after surgery
• • Patients who have had chemotherapy or radiotherapy
• • Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, electronic infusion pumps, etc), because such devices may be displaced or malfunction
• • Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
• • For patients who have undergone surgical resection prior to joining the study, in whom baseline magnetic resonance (MR) images exhibit enough signal degradation (due to susceptibility artifact in the region of the surgical bed) such that the data are uninterpretable will be excluded